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ABSTRACT 
BACKGROUND. There is currently a lack of evidence for the relative effectiveness of 
partial resection (PR) and total resection (TR) before managing abdominal aortic 
graft infection (AGI). Most authorities agree that TR is mandatory for intracavitary 
AGI in patients with favorable conditions but there is an increasing number of 
patients with severe comorbidities for whom this approach is not suitable, resulting 
in a prohibitive mortality rate. The purpose of this study was to determine the most 
appropriate indication for TR or PR. 
METHODS. A meta-analysis was conducted on the rates of early/late mortality, 
amputations and reinfection. A meta-regression was performed with 8 variables: 
patient age, male prevalence, presence of virulent or nonvirulent organisms, 
urgency, omentoplasty and follow-up. 
RESULTS. Twenty-one studies and 1.052 patients were included. For TR and PR the 
rates of early mortality and reinfection were 16.8% and 10.5%, 11% and 27% 
respectively. For TR urgency and male gender were associated with increased rate of 
early mortality and male gender, PDF and virulent organisms were associated with 
increased risk of reinfection. For PR no statistical correlation was analyzable except 
for PDF with increased risk of reinfection. 
CONCLUSION. Early mortality rates are higher for TR and reinfection rates are higher 
for PR. For TR early mortality increases in urgent cases and it is suggested that 
alternative option must be discussed, reinfection decreases in the presence of 
nonvirulent organisms and TR seems optimal. For TR and PR reinfection increases in 
presence of PDF and alternative technique may be more appropriate. 
Keywords: - meta-analysis- outcomes of in situ reconstruction- infected aortic graft- 
total or partial removal. 
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INTRODUCTION
Aortic graft infection (AGI) is a life-threatening complication that occurs in 1% to 5% 
of patients who undergo conventional abdominal aortic surgery1-4,causing major 
morbidity, mortality, and economic cost5-7 .The prognosis depends on a multitude of 
factors including the underlying condition of the patient, urgency, presence of 
sepsis, virulence of the infecting organism(s), infection linked to prosthetic-duodenal 
fistula (PDF), and finally the surgical modalities of AGI treatment8-12. Contemporary 
management of AGI includes: 
- total resection of the infected graft, with either concomitant extra-anatomic 
reconstruction (EAR) or in situ reconstruction (ISR)13 
- partial resection (PR) 
In a recent meta-analysis, ISR was associated with a lower occurrence of events than 
EAR, and these results suggest that ISR may be considered as a first-line treatment14. 
Most authorities agree that total resection (TR) of the infected aortic graft is 
mandatory for intracavitary AGI15-17. However, extensive dissection to achieve total 
graft excision could disrupt the collateral blood supply and create a problem of 
pelvic and limb ischaemia18,19. Moreover, the total graft removal approach is clearly 
not feasible in some patients with severe comorbidites or extremely hostile 
abdomens20.  
On the other hand, partial graft preservation techniques are becoming increasingly 
popular as a method to treat established graft infection21-25. However, partial 
resection (PR) varies widely in the series, there is no consensus for assessing the 
extent of infection on the graft, indications are not clear, and outcomes reported in 
the series are limited. 
Despite a considerable number of publications including total or partial excision of 
the infected aortic graft there has been no systematic review or meta-analysis to 
assess the clinical outcomes of ISR associated with the 2 excision modalities. The 
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purpose of this meta-analysis was to determine the most appropriate indication for 
TR or PR of an infected aortic graft in light of the different outcomes after ISR.   
Methods 
The present review was conducted in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines 26. A review 
protocol can be accessed online in Appendix A. 
Research Strategy : 
A literature search was performed using MEDLINE and EMBASE, covering all studies 
published in English between January 1997 and June 2017, as well as 
recommendations for reporting treatment of aortic graft infections27. The medical 
subject headings (MeSH) used for the search were aortic, graft, and infection. The 
following key words were also used: Rifampin or Rifampicin-coated polyester grafts, 
polyester or Dacron, cryopreserved allografts, autogenous veins, Silver-coated 
polyester, prosthetic-duodenal-fistula, and partial resection (PR), or total 
resection(TR).  
Inclusion and exclusion criteria were defined to determine the selection of clinical 
studies (detailed online in Appendix B). References from identified studies were also 
reviewed to ensure that all relevant published papers had been identified. The 
electronic search was accompanied by a manual search of all the reference lists 
from the relevant articles. 
Study Selection: 
The selected clinical studies included ISR with autogenous veins, cryopreserved 
allografts and synthetic prostheses that were either standard, Rifampicin bonded or 
Silver coated polyesters. They also included PDF, (classified as a separate entity27), 
and the modality of intervention (emergency or planned) for assessment in the 
meta-regression analysis. Special attention was paid to the extent of the resection: 
total resection (TR) or partial resection (PR) of the infected aortic graft. 
With no prior knowledge of the authors or the outcomes of the selected 
publications, two reviewers used a standardized scoring system to rate the clinical 
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that did not   rate above the 18/28 quality score threshold  were excluded from the 
meta-analysis. All studies that did meet the inclusion and exclusion criteria were 
found to have a quality score above this threshold. These assigned quality scores 
were not used to compare the results of individuals studies. 
Data Extraction: 
When the available written information was insufficient for the meta-analysis, 
strenuous efforts were made to contact the principal investigator and obtain the 
necessary information in order to reduce the effect of publication bias. 
Two reviewers independently extracted the data from each selected publication. 
Inter-rater reliability was high.  The primary outcome measures were early (< 1 year) 
and late mortality (> 1 year)12. Additional data was extracted regarding rates of 
amputation and reinfection of the in situ graft”. 
Statistical Analysis: 
The purpose of this meta-analysis was to statistically compare the estimated mean 
occurrence rate of the following events: early (operative) /late mortality, 
amputation and reinfection. These rates were pooled from studies including the 
following variables: age, male prevalence, emergency operation, PDF, omentoplasty, 
microbiology data and follow-up. 
We used Comprehensive Meta-Analysis software to carry out this project. With this 
software, we estimated the pooled values of the parameters (estimation of 
frequency in meta-analysis) as well as their confidence intervals. 
We estimated the heterogeneity using Cochran’s Q test with the point estimate of I2. 
Heterogeneity was visually analyzed with a Forestplot, and quantified using 
Cochran’s Q test with the point estimate of I2. If heterogeneity was present (Q 
statistic at 5%, and I2 high), we took it into account using the DerSimonian and Laird 
random-effects method, and if not, using the fixed-effects method.  
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As there were no randomized trials, when we compared 2 groups, we used a 
percentage comparison test between the 2 independent groups (chi-squared test). 
We then researched the publication bias using the Egger method and the trim and 
fill method. With the latter, we reassessed the results and their confidence interval, 
taking into account potential missing studies belonging to the analyzed pool. Since 
the percentage tests generally concerned more than 2 modalities, we used the chi-
squared test to compare one level with the other levels. When appropriate, 
correction for multiple comparisons was performed for subgroup analysis. 
Meta-régressions were carried out to estimate the heterogeneity effects according 
to confounding variables, as defined: patient age (above the mean age, patients 
were defined as older), male prevalence, emergency ISR, presence of PDF, virulent 
infectious organisms (ie, Staphylococcus aureus, Enterobacteriaceae, beta-hemolytic 
Streptococcus, Pseudomonas) 29, non-virulent infectious organisms (ie, commensal 
organisms or negative bacteriological cultures) 29, omentoplasty and follow-up. We 
performed meta-regressions when the number of studies was higher than or equal 
to 3. The outcome of these methods enabled us to discuss the final results and 
justify our propositions. 
Besides the meta-analysis software, we used the SAS software version 9.3 at the 
University Institute of Clinical Research of Montpellier (UPRES 2415 Team. Aide à la 
décision médicale personnalisée-Personalized support for therapeutic decision). 
Results 
A total of 2,327 unique articles were identified, 382 of which were retrievied for 
analysis. Inclusion/exclusion criteria were met by 31 publications. Ten articles were 
excluded using a standard scoring system. Twenty-one studies and 1,052 patients, 
were included in this meta-analysis (detailed online in Appendix D). They were 
classified according to the extent of infection of the aortic graft (either as P0 graft 
infection of cavitary graft, eg. aorto-aortic or aorto- bi-iliac graft, or as P2 graft 
infection of extra-cavitary graft, eg.  infection of extra-cavitary portion of the graft 
whose origin is cavitary, eg.  aorto-bifemoral graft) 27, and the extent of resection of 
the infected aortic graft: total resection( TR), or partial resection  (PR). 
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Nearly all the studies used in this meta-analysis were retrospective and 
observational. As expected, none of the studies were randomized control trials. The 
primary characteristics of clinical studies and covariates used in this meta-analysis 
are detailed online in Appendix E 8-11,24,25,30-44. 
The mean number of patients across all studies was 50 ( range: 2-220).There were 
887 TR (84 %), and 165 PR (16%) with 6 studies (382 patients) combining TR  (259 
patients) and PR (123 patients) 10,31,34,36,40,42, 11 studies with solely TR (628 patients) 
8,9,11,30,32,33,35,37,41,43,44, and 4 studies with solely PR (42 patients) 24,25,38,39. 
The mean patient age for the entire series was 66.1 years (range 29-91 years); the 
mean age of patients with TR and PR was 65.1 years (range 29-86 years), and 67.7 
years (range 43-91 years) respectively (P=NS). 
Different comorbidities and risk factors, detailed online in Appendix E, were not 
available in all the studies, and therefore statistical comparison between the 
outcomes of the patients with TR and PR must be interpreted with caution. 
1°Outcomes after total resection: 
a) Early mortality:
Separate sets of data were available for 13 studies (642 patients).After correction of 
bias the adjusted  early mortality rate was 16.8%; 95% CI: 11.8%-22.6%, (Table 1A). 
In a meta-regression analysis (Table 1B) urgency of the intervention (P = .001), male 
prevalence (P< .0001 ) and omentoplasty  (P< .0001)were associated with increased 
risk of    early mortality (Figure 1A, 1B, 1C). 
b) Late mortality:
Separate sets of data were available for 11 studies (585 patients). After correction of 
bias, the adjusted late mortality rate was 28.5%; 95% CI: 25%-32%, (Table 1A).In a 
meta-regression analysis (Table 1B), only omentoplasty (P= .006) was associated 
with decreased risk of late mortality (Figure 2). 
c) Reinfection:
Separate sets of data were available for 16 studies (808 patients) .  After correction 
of bias the adjusted reinfection rate was 11%;  95% CI: 6%-19% (Table 1A).In a meta-
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regression analysis  (Table1C),  patient age    (P< .0001),presence of PDF (P = .002), 
and virulent infectious organisms (P = .001)   were associated with increased risk of 
reinfection (Figure 3A, B, C), whereas nonvirulent infectious organisms  (P< .0001)   
was associated with decreased risk of reinfection (Figure 3D). 
d) Amputation :
Separate sets of data were available for 14 studies (660 patients)  . After correction 
of bias, the adjusted  amputation rate: 8.1%;  95% CI: 6%-11%, (Table 1A).In a meta-
regression analysis, (Table1C), presence of PDF (P = .042), and length of follow-up (P 
= .006), were both  associated with increased risk of  amputation (Figure 4), whereas 
male prevalence was associated with decreased risk of amputation (P = .026). 
2° Outcomes after partial resection: 
a) Early mortality:
Separate sets of data were available for 6 studies (68 patients). After correction of 
bias, the adjusted operative mortality rate: 10.5%; 95% CI: 4%-22%, (Table 2). In a 
meta-regression analysis (Table 1B), there was no analyzable correlation between 
the variables considered   (P > .05). 
b) Late mortality:
Separate sets of data were available for 5 studies (49 patients). After correction of 
bias, the adjusted late mortality rate: 18%; 95% CI: 9%-32%, (Table 2).In a meta-
regression analysis (Table 1B), there was no analyzable correlation between the 
variables considered (P > .05). 
c) Reinfection:
Separate sets of data were available for 10 studies (165 patients). After correction of 
bias, the adjusted  reinfection rate: 27%; 95% CI: 12%-50%, (Table 2). In a meta-
regression analysis (Table 1C), only the presence of PDF (P=.01)  was associated with 
increased risk of reinfection (Figure 5). 
d) Amputation:
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 Separate sets of data were available for 7 studies (74 patients). After correction of 
bias   the adjusted amputation rate:  15.4%; 95% CI: 8%-29%, (Table 2). In a meta-
regression analysis (Table 1C), there was no analyzable correlation  with the 
variables considered (P > .05).  
Discussion 
Treatment for AGI is still very much under discussion, and optimal management of 
patients is still an unsolved challenge. Miller 45 was one of the first to introduce the 
concept of partial aortic graft removal accomplished with a 13% early mortality rate, 
33% persistent infection  and thereby challenged the paradigm of entire aortic graft 
excision   .
The results from the present meta-analysis are summarized in Table 1A, 2 : 
early/late mortality, reinfection and amputation rates for TR and PR are 16.8% and 
10.5%, 28.5% and 18%, 11% and 27%, and 8.1% and 15.4% respectively  . They are in 
keeping with previously published reviews/ meta-analyses 12-14.However, statistical 
comparison with TR and PR must be weighted with the limitations of meta-analysis 
and interpreted with caution (see below). 
Perhaps the most difficult aspect of managing AGI is deciding on the appropriate 
treatment for any given patient : 
- regarding the manifestations of the patients concerned, most authorities agree 
that TR is mandatory for intra-cavitary AGI in patients with favorable conditions13,15-
17, but there is an increasing number of patients with severe comorbidities and for 
whom this approach would be inappropriate and even ill-advised, resulting in a 
prohibitive mortality rate. Thus, it was suggested that the premise of a more limited 
aortic reconstruction might benefit the patient by avoiding aortic clampage, 
reducing  physiological stress, and limiting the extent of dissection needed to excise 
the entire graft.  
- on the other hand, concerning the extent of AGI, numerous authors   38-41, 43-45 agree 
that for pangraft infection, TR is the most advisable, and when AGI is localized, PR 
appears   recommendable24,25. However there are numerous other clinical scenarios 
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where optimal treatment is not clearly defined. To make the most appropriate 
decision, evaluation of outcomes in each situation may be helpful. 
 Early and late mortality: 
In the meta-analysis, operative mortality rates were higher for TR than PR, with 
16.8% and 10.5% respectively (Table 1A, 2).   
In the literature review, urgency of the intervention for AGI is one of the most 
important determinants of in-hospital mortality 9,12,18,40,46-52.    Not surprisingly, in the 
meta-regression analysis (Table 1B), urgency had a negative correlation with 
operative mortality for TR (Figure 1A), but no correlation was analyzable for PR. 
Hence, in order to lower operative mortality in an emergency situation, there may 
be fewer surgical options available for patients who cannot be stabilized long 
enough to select the most appropriate surgical option. In this difficult situation, it is 
suggested that endovascular bridge therapy might be the only realistic             option 
13, 53-56. 
Male gender was prevalent in this study (online Appendix E). In the meta-regression 
(Table 1B), male gender had a negative correlation with operative mortality for TR 
(Figure 1B), but no correlation was analyzable for PR.  In the literature female 
gender was considered as an independent predictor for operative    mortality 18. In 
the results of the present study, the higher operative mortality observed in males is 
probably related to the epidemiology of cardiovascular disease and the prevalence 
of cardiovascular risks in males 57. 
In 1987,Walker  was one of the first to propose  omentoplasty for protection  
against reinfection  58, and its benefits were confirmed by numerous studies for both 
TR and PR 9,11,13,18, 37,54 In the meta-regression(Table 1B), the negative correlation 
between omentoplasty and operative mortality is not clear (Figure 1C), because  
omentoplasty is considered a safe procedure, associated with a moderate number 
of post-operative complications 59. In our opinion, such discrepancy could only be 
explained by the differences amongst patients undergoing surgical procedures, 
particulary any underlying diseases. 
In the meta-analysis, late mortality rates were higher for TR than for PR with 28.5% 
and 18% respectively (Table 1A, 2), and in the meta-regression, omentoplasty had a 
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positive correlation with late mortality for TR (Figure 2), although no correlation was 
analyzable for PR (Table 1B). Such benefits for patients with omentoplasty are 
probably linked to the decrease in late infectious mortality caused by dehiscence of 
anastomosis and fatal hemorrhage. 
Reinfection and amputation: 
In the results of the meta-analysis reinfection rates were higher for PR than for TR, 
with 27% and 11% respectively (Table 1A, 2). The literature 60-62 supports this idea 
that complete graft excision minimizes the risk of reinfection and Ricotta reported 
persistent or recurrent infection in 25% of the grafts treated with PR but no 
reinfection after TR 62.   
In the literature there is a link between reinfection and patient age 10,11,63, presence 
of PDF10,12,18,47,48,64 and virulent10,25,32,43,48,65-67 or nonvirulent64,68-70 infecting 
organisms. In the meta-regression (Table 1C), age and virulent organisms had a 
negative correlation with reinfection for TR (Figure 3A, C), nonvirulent organisms 
had a positive correlation for TR (Figure 3D), and PDF had a negative correlation for 
TR and PR (Figure 3B, Figure 5). The results of the present study suggest  that in 
order to lower reinfection rates in the presence of nonvirulent organisms, TR 
appears optimal. In the presence of PDF, neither TR nor PR were advisable before in 
situ reconstruction. It was suggested that extra-anatomic bypass still has an 
important role 18,71, and staged en ovascular approach with early conversion to in 
situ repair with a vein or prosthetic graft with omental wrapping may achieve the 
best results55 . For older patients or in the presence of virulent organisms fewer 
surgical options may have been available because TR was not recommendable and 
PR had no analyzable correlation. Thus, for older patients or in the presence of 
virulent organisms, if the patient is hemodynamically stable and not septic, it has 
been suggested that percutaneous drainage of peri-aortic abcesses or fluid 
collections, and intensive treatment of infection or comorbidities could be done 
before more extensive operation 72, and consequently, extra-anatomic 
reconstruction 18 or in situ reconstruction with femoral veins 12,14 may be the most 
appropriate . 
Omentoplasty was recommended to lower reinfection rates9,11,13,18,24,31,37,58. 
Unfortunately, in the present study, no correlation was analyzable. However, 
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omentoplasty is not always feasible, for instance in the event of extra-cavitary graft 
infection or a retroperitoneal approach 24,25. 
In the results of the meta-analysis, amputation rates were higher for PR than for TR, 
with 15.4% and 8.1% respectively (Table 1A, 2). Unsurprisingly, in the meta-
regression (Table 1C), amongst the population of patients with vascular risks, follow-
up had a negative correlation with amputation for TR (Figure 4), and the results for 
PR were not analyzable. The nature of the conduit was probably the major factor 
12,14 .  
This meta-analysis suggests indications for PR or TR of infected aortic graft according 
to patient manifestations and the bacteriologic data, but unfortunately it could not 
provide any recommendations as to how to make future decisions regarding patient 
treatment because this study is a meta-analysis of retrospective studies, not 
prospective, nor randomized. Moreover, observational studies used in this meta-
analysis were difficult to analyze and interpret because the discrepancy between 
patient numbers in each group (887 TR vs 165 PR) caused a problem for statistical 
comparison. This drawback was owing to the lack of standardized indications for TR 
or PR in the series, and not this meta-analysis. 
Finally, the main finding of this study was the reduced post-operative mortality with 
PR at the price of the increased late reinfection. Therefore, management of AGI is 
clearly not easy, and is still under discussion. In order to define an optimal strategy, 
decisions must be tailored following the input of all clinicians involved, i.e. vascular 
surgeon, microbiologist/infectious disease physician, interventional and imagist 
radiologist and others, taking due cognizance of the individual patient’s condition 
and state 13, 73-77. Moreover, operative flexibility is required should unexpected 
difficulties arise during the intervention. 
Study Limitations: 
Some limitations, mostly related to potential bias, are encountered in this meta-
analysis: 
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-  Studies selection bias: 
 The selection process for publications, notably the manner in which we pooled the 
data from individual studies, may be a source of bias. Inclusion/exclusion criteria 
were defined in attempt to limit selection bias. For example, infected aortic 
aneurysms were excluded because, etiology, bacteriology and treatment results are 
different from those of AGI 13,48,78, and the series combining total and partial 
removal of infected aortic grafts were excluded if the results were not 
differentiated. On the other hand, our inclusion/exclusion criteria may have biased 
the outcome of the meta-analysis. For example, we only considered clinical s udies 
whose results were reported in the English language. Hence, results extracted from 
medical journals in languages other than English were excluded. We believe that 
publication bias was limited by the use of the Funnel plots and complementarity 
validation tests. 
  -  Outcome reporting bias: 
Nearly all studies analyzed were retrospective and observational. Consequently, 
there are problems concerning inter-study heterogeneity and selection        bias 
79 despite reasonable efforts to perform tests of heterogeneity (Table 1A, 2):  
- it is possible that some significant medical considerations were not available in a 
number of studies. These include, cigarette smoking (not reported in the majority of 
the series) which is associated with increased surgical risk of site infection80,time to 
clinical presentation of the infection divided into early and late presentation 
(<3months or after 3 months)23, infection presented, and specific informations on 
the pre-operative status of the patients: coronary heart disease, HTA, diabetes 
mellitus, renal failure, chronic obstructive pulmonary disease, ASA score, 
immunosuppression, history of neoplasm, body mass index 81, anatomic 
considerations (hostile abdomens, poor pelvic collateral blood supply, tight 
attachment of the infected graft to the iliac vessels and the ureter, aortic graft 
involving the renal or visceral aortic segment), and so forth. These risk of bias across 
the studies create reservations regarding the comparison of outcomes after TR and 
PR27. For example, partial graft removal of the infected aortic graft was probably 
performed in a group of patients who have a more significant operative risk 
compared to those who underwent total graft removal, but these differences, 
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which the Publisher may post on the Article. It is not permitted to frame or use framing techniques to enclose any trademark, logo, or other proprietary information of the Publisher. 
despite reasonable efforts, cannot be shown in the different studies. This drawback 
concerns the reported studies themselves and not this meta-analysis. 
- there is also a possibility that some specific aspects of treatment were not 
available, yet had an impact on perioperative outcomes: drainage of peri-prosthetic 
abscesses, use of sartorius flap21 or Vacuum- assisted closure device, the experience 
of each center (number of patients treated per year for AGI), lack of consensus 
concerning the nature and duration of postoperative antibiotherapy82, and so forth. 
 As a result, the eligible sample size for analysis was considerably reduced. However, 
this drawback concerns the reported studies themselves and not this meta-analysis. 
   -  Limits of meta-regression: 
  The associations derived from meta-regression are observational and have a 
weaker interpretation than the causal relationships derived from randomized 
comparisons. Data dredging is the main pitfall in reaching reliable conclusions from 
meta-regression, and pre-specification of covariates is heightened. Therefore, 
special attention was paid to selected relevant covariates in this study. For instance, 
the nature of the conduit has an impact on operative outcomes 12,14, but these 
differences could not be captured in the present meta-analysis  owing to 
heterogeneity between PR and TR. 
Conclusion
 The results of this meta-analysis suggest that operative mortality rates are higher 
for TR , and reinfection rates are higher for PR . 
Operative mortality increases  in urgent cases for TR . Hence in order to lower 
operative mortality in an emergency situation it is suggested that alternative option 
must be discussed. 
  Reinfection decreases for TR in the presence of nonvirulent infectious organisms, 
and in order to lower reinfection TR seems optimal.  In the presence of virulent 
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organisms and PDF reinfection increases for TR and alternative techniques may be 
most appropriate.   
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Legends of Tables and Figures  
Table I: Meta-Analysis and Heterogeneity Tests of the Results for Total Resection. 
Table II: Meta-Regression Analysis of the Risk of Operative and Late Mortality According to Male 
gender, Omentoplasty and Emergency. 
 TR: total resection; PR: partial resection. 
Table III: Meta-Regression Analysis of the Risk of Reinfection and Amputation According to Age, 
PDF,Virulent or Nonvirulent Infecting Organisms, Follow-up and Male gender. 
TR: Total Resection; PR: Partial Resection, PDF: prosthetic-duodenal fistula, % male : male gender. 
Table IV: Meta-Analysis and Heterogeneity Tests of the Results for Partial Resection. 
Figure 1A: Meta-regression plot of emergency against early mortality for total resection (10 
studies, P = .001, Tau2 = .10). 
Figure 1B: Meta-regression plot of presence of male gendre against early mortality for total 
resection (10 studies, P = 0, Tau2 = .144). 
Figure 1C: Meta-regression plot of omentoplasty against early mortality for total resection 
(3studies, P = 0, Tau2 = .054). 
Figure 2: Meta-regression plot of omentoplasty against late mortality for total resection (3 studies, 
P = .006, Tau2 = 0). 
Figure 3A: Meta-regression plot of age against reinfection for total resection (11 studies, P = 0, 
Tau2 = .75 ). 
Figure 3B: Meta-regression plot of presence of prosthetic-duodenal fistula against reinfection for 
total resection (11 studies, P=.002, Tau2 = .85) 
Figure 3C: Meta-regression plot of virulent infectious organisms against reinfection for total 
resection (11studies, P = .001, Tau2 = 1.24). 
Figure 3D: Meta-regression plot of nonvirulent infectious organisms against reinfection for total 
resection (10 studies, P = 0, Tau2 = .33). 
Figure 3D: Meta-regression plot of presence of prosthetic-duodenal fistula against reinfection for 
total resection (11 studies, P=.002, Tau2 = .85) 
Figure 4: Meta-regression plot of follow-up against amputation for total resection (11 studies, P = 
.006, Tau2 = .15).  
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Figure 5: Meta-regression plot of prosthetic-duodenal fistula against reinfection for partial 
resection (4 studies, P = .01, Tau2 = 0). 
No of 
trials 
analysis 
I² 
statistic 
P for 
heterogeneity 
Method (fixed 
or Random-
effects Model) 
Event Rate IC Event 
Rate 
Random model if heterogeneity test is 
significant or fixed model if not 
- Operative mortality 
13 61.3 0.002 Random 0.162 0.113-0.226 
- Reinfection 16 69.7 0 Random 0.064 0.034-0.117 
- Amputation 14 29.7 0.14 Fixed 0.068 0.048-0.095 
- Late mortality 11 37.4 0.1 Fixed 0.279 0.243-0.319 
Event rates after corrections of 
selection bias (Dural and test is trim 
and fill) 
- Operative mortality 0.168 0.118-0.226 
- Reinfection 0.110 0.06-0.19 
- Amputation 0.081 0.06-0.11 
- Late mortality 0.285 0.250-0.320 
Table   I
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Event Variables group Study 
N 
Slope Slope 95 % IC p-value T² 
% male 
TR 10 0.04 -0.02-0.06 0 0.144 
PR 3 0.06 -0.05-0.17 0.27 0 
Omentoplasty 
TR 3 0.05 0.02-0.08 0 0.054 
PR No correlation analyzable 
Operative 
Mortality Emergency 
TR 10 0.04 0.02-0.06 0.001 0.10 
PR    No correlation analyzable 
Late 
Mortality Omentoplasty 
TR 3 -0.09 -0.16-(-0.03) 0.006 0 
PR No correlation analyzable 
Table    II
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Event Variables gr
ou
p 
Study 
N 
Slope Slope 95 % IC p-value T² 
Age 
TR 11 0.29 0.12-0.46 0 0.75 
PR 4 0.16 -0.03-0.35 0.095 1.76 
PDF 
TR 11 0.04 -0.01-0.06 0.002 0.85 
PR 4 0.07 0.01-0.13        0.01 0 
Reinfection 
Virulent 
TR 11 0.06 0.02-0.10 0.001 1.24 
PR  5   -0.00009 -0.18-0.18  0.99 0 
Non Virulent 
TR 10 -0.09 -0.13-(-0.05) 0 0.33 
PR  3 -0.02 -0.82-0.77 0.95 0 
PDF 
TR 11 0.02 0.00-0.05 0.042 0.28 
Follow-up 
% male 
P
R
p 
P
R 
     3  
    11 
      4 
     11 
 3 
0.02 
0.04 
-0.02 
-0.04 
0.05 
-0.07-0.11 
0.01-0.06 
-0.11-0.06 
0.08-(-0.005) 
-0.06-0.16 
0.66 
0.006 
0.57 
0.026 
0.34 
     0.09 
     0.15 
         0 
      0.32 
         0 
 Table      III 
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No of 
trials 
analysis 
I² 
statistic 
P for 
heterogeneity 
Method (fixed 
or Random-
effects Model) 
Event Rate IC Event 
Rate 
Random model if heterogeneity test is 
significant or fixed model if not 
- Operative mortality 
6 0 0.8 Fixed 0.073 0.027-0.18 
- Reinfection 10 69.1 0.001 Random 0.189 0.081-0.383 
- Amputation 7 0 0.67 Fixed 0.095 0.041-0.206 
- Late mortality 5 0 0.64 Fixed 0.162 0.079-0.305 
Event rates after corrections of selection 
bias (Dural and test is trim and fill) 
- Operative mortality 
0.105 0.04-0.22 
- Reinfection 0.27 0.12-0.50 
- Amputation 0.154 0.08-0.29 
- Late mortality 0.18 0.09-0.32 
Table    IV 
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